Has Scott McHam, DO received payments from drug or device companies?

Yes. Drug and device makers reported $32,846 in general payments to Scott McHam, DO across 184 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Scott McHam, DO did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Scott McHam, DO come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Scott McHam, DO

Hematology & Oncology · Lincoln, NENPI 1235170473

Payments from drug & device makers

$32,846in general payments, 2019–2025

Across 184 payments — averaging $178.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$30K
E.r. Squibb & Sons, L.L.C.$443
Pfizer$197
Johnson & Johnson$172
Pharmacyclics LLC, An Abbvie Company$152
Daiichi Sankyo Inc.$116
plus $2K from 40 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	17	$29,942
E.r. Squibb & Sons, L.L.C.	26	$443
Pfizer	11	$197
Johnson & Johnson(2 entities)	8	$172
Pharmacyclics LLC, An Abbvie Company	8	$152
Daiichi Sankyo Inc.	5	$116
Seagen Inc.	7	$115
Eisai Inc.	7	$115
AstraZeneca(2 entities)	6	$109
AbbVie	5	$105
Bristol Myers Squibb	6	$102
Tersera Therapeutics LLC	6	$102
Novartis	6	$94
EMD Serono, Inc.	5	$92
Gilead(2 entities)	6	$91
AVEO Pharmaceuticals, Inc.	3	$72
Amgen	4	$71
Sanofi	4	$67
Genentech USA, Inc.	4	$63
Astellas Pharma US Inc	3	$49
Incyte Corporation	3	$49
Array Biopharma Inc	2	$47
Bayer	3	$43
Lilly USA, LLC	3	$38
Takeda Pharmaceuticals U.S.A., Inc.	2	$32
Agios Pharmaceuticals, Inc.	2	$30
CTI Biopharma Corp.	2	$28
Exelixis Inc.	2	$27
Octapharma USA, Inc.	1	$22
Regeneron Healthcare Solutions, Inc.	1	$21
Ipsen Biopharmaceuticals, Inc	1	$21
Genmab U.S., Inc.	1	$21
Sobi, Inc	1	$18
Blue Earth Diagnostics	1	$17
GSK	1	$15
Karyopharm Therapeutics Inc.	1	$15
Novocure Inc.	1	$15
Puma Biotechnology, Inc.	1	$15
Blueprint Medicines Corporation	1	$15
Lexicon Pharmaceuticals, Inc.	1	$14
Heron Therapeutics, Inc.	1	$14
Jazz Pharmaceuticals Inc.	1	$14
Taiho Oncology, Inc.	1	$12
Verastem, Inc.	1	$12
Epizyme, Inc.	1	$12
Dova Pharmaceuticals	1	$11

How this compares

$32,846 in reported general payments places this provider in the 50th percentile of 73 hematology & oncology providers in Nebraska.

See all hematology & oncology providers in Nebraska →

Medicare billing

Part B allowed, 2024

$5,028,841

Medicare patients

1,121

Services billed

249,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Lincoln

Kailash MosalpuriaLincoln$4.2M
Madhu MidathadaLincoln$1.1M
Mark HutchinsLincoln$1.1M
Eric AveryLincoln$1.1M
Steven DunderLincoln$612K
Stacey KnoxLincoln$573K
Alan BergLincoln$396K
Joni TilfordLincoln$181K
Nathan GreenLincoln$136K
Melissa CetakLincoln$6K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →